• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    3/21/22 12:45:34 PM ET
    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACLX alert in real time by email

     

     

    During Monday's session, 39 stocks hit new 52-week lows.

    Interesting Facts About Today's 52-Week Lows:

    • The largest company in terms of market cap to set a new 52-week low was Nuveen Municipal Value (NYSE:NUV).
    • Palisade Bio (NASDAQ:PALI) was the smallest firm on a market cap basis to set a new 52-week low.
    • Vallon Pharmaceuticals (NASDAQ:VLON) shares dropped the most, trading down 70.3% to reach its new 52-week low.
    • Cass Information Sys (NASDAQ:CASS) shares actually gained 0.16%, rebounding after it reached its 52-week low.

    Over the course of trading on Monday, the following stocks hit new 52-week lows:

    • Nuveen Municipal Value (NYSE:NUV) shares set a new yearly low of $9.42 this morning. The stock was down 0.62% on the session.
    • Cytek Biosciences (NASDAQ:CTKB) stock hit a yearly low of $11.71. The stock was down 3.36% for the day.
    • Immunogen (NASDAQ:IMGN) stock broke to a new 52-week low of $3.83 on Monday. Shares of the company traded down 17.68%.
    • BLACKROCK MUNIYIELD (NYSE:MYI) stock hit a new 52-week low of $12.38. The stock was down 0.72% on the session.
    • Nuveen Dynamic Municipal (NYSE:NDMO) shares made a new 52-week low of $13.42 on Monday. The stock was down 1.66% for the day.
    • Blackrock Muniholdings (NYSE:MHD) stock achieved a new 52-week low on Monday morning, hitting $14.17 and moving down 0.58%.
    • Children's Place (NASDAQ:PLCE) shares made a new 52-week low of $49.84 on Monday. The stock was down 6.53% for the day.
    • Bird Global (NYSE:BRDS) shares made a new 52-week low of $2.40 on Monday. The stock was down 5.23% for the day.
    • HCM Acquisition (NASDAQ:HCMA) shares made a new 52-week low of $9.82 on Monday. The stock was down 0.63% for the day.
    • Cass Information Sys (NASDAQ:CASS) stock drifted down 0.16% on Monday morning to hit a new 52-week low of $37.84.
    • Arcellx (NASDAQ:ACLX) stock drifted down 4.24% on Monday morning to hit a new 52-week low of $14.56.
    • Adagio Therapeutics (NASDAQ:ADGI) shares hit a yearly low of $4.38. The stock was down 9.56% on the session.
    • SeaSpine Holdings (NASDAQ:SPNE) shares set a new yearly low of $10.71 this morning. The stock was down 1.23% on the session.
    • Graphite Bio (NASDAQ:GRPH) shares were down 12.93% for the day, having made a 52-week low of $6.97.
    • Blackrock CA Muni Income (NYSE:BFZ) stock hit a yearly low of $12.38. The stock was down 0.71% for the day.
    • Nuveen New York Quality (NYSE:NAN) stock broke to a new 52-week low of $12.32 on Monday. Shares of the company traded down 0.72%.
    • Vigil Neuroscience (NASDAQ:VIGL) shares set a new 52-week low of $9.26. The stock traded down 7.48%.
    • Delaware Investments (AMEX:VFL) shares fell to $12.53 on Monday, setting a new 52-week low with a shift of down 1.02%.
    • Akanda (NASDAQ:AKAN) stock set a new 52-week low of $6.79 on Monday, moving up 10.0%.
    • BNY Mellon Municipal Bond (NYSE:DMB) stock drifted down 0.94% on Monday morning to hit a new 52-week low of $12.65.
    • Invesco Trust For Invnt (NYSE:VTN) shares were down 0.92% for the day, having made a 52-week low of $11.83.
    • Hooker Furnishings (NASDAQ:HOFT) shares made a new 52-week low of $19.06 on Monday. The stock was down 1.28% for the day.
    • Alpine 4 Holdings (NASDAQ:ALPP) stock hit a new 52-week low of $1.09. The stock was down 3.36% on the session.
    • Meihua International (NASDAQ:MHUA) shares were down 5.22% for the day, having made a 52-week low of $6.12.
    • Quantum (NASDAQ:QMCO) stock broke to a new 52-week low of $2.30 on Monday. Shares of the company traded down 2.31%.
    • Nuveen Massachusetts (NYSE:NMT) shares hit a yearly low of $12.48. The stock was down 0.48% on the session.
    • Emclaire Financial (NASDAQ:EMCF) shares made a new 52-week low of $25.23 on Monday. The stock was up 1.98% for the day.
    • Borqs Technologies (NASDAQ:BRQS) shares set a new 52-week low of $0.24. The stock traded down 7.06%.
    • Allena Pharmaceuticals (NASDAQ:ALNA) stock hit $0.26 on Monday morning, setting a new 52-week low for a change of down 37.83%.
    • Vallon Pharmaceuticals (NASDAQ:VLON) stock broke to a new 52-week low of $2.10 on Monday. Shares of the company traded down 70.3%.

     

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX
    $ADGI
    $AKAN
    $ALNA

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Arcellx Inc.
    $ACLX
    1/7/2026$100.00Buy
    UBS
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Arcellx Inc.
    $ACLX
    12/22/2025$100.00Overweight
    Wells Fargo
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Arcellx Inc.
    $ACLX
    11/18/2025Peer Perform
    Wolfe Research
    Quantum Corporation
    $QMCO
    11/14/2025Market Perform → Outperform
    Northland Capital
    Arcellx Inc.
    $ACLX
    10/16/2025$129.00Buy
    Stifel
    More analyst ratings

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum to Announce Fiscal Third Quarter 2026 Financial Results on February 17, 2026

    Quantum Corporation (NASDAQ:QMCO) ("Quantum" or the "Company"), today announced it will release financial results for its fiscal third quarter 2026 on Tuesday, February 17, 2026, after the markets close. Hugues Meyrath, Chief Executive Officer, and William White, Chief Financial Officer, will host a conference call on Tuesday, February 17, 2026 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the Company's financial results and business outlook. Analysts and investors are invited to join the conference call using the following information: Date: Tuesday, February 17, 2026 Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Call Number: 1-866-424-3436 International Call Number: +

    2/9/26 4:05:00 PM ET
    $QMCO
    Electronic Components
    Technology

    Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

    Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. Th

    2/9/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BlackRock Announces Completion of Certain Municipal CEF Reorganizations and Adoption of Discount Management Program

    BlackRock Advisors, LLC announced today each of the closed-end funds named below (each, a "Fund" and collectively, the "Funds") have completed their reorganizations or mergers, as applicable (each, a "Reorganization" and collectively, the "Reorganizations"). Additionally, each of the Survivor Funds, as identified below, adopted a Discount Management Program that seeks to enhance long-term shareholder value via periodic liquidity events if certain conditions are met (see below for details). Reorganization of BlackRock California Municipal Income Trust (BFZ) with and into BlackRock MuniHoldings California Quality Fund, Inc. (MUC) Reorganizations of BlackRock New York Municipal Income Tr

    2/9/26 8:34:00 AM ET
    $BFK
    $BFZ
    $BLE
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    SEC Filings

    View All

    SEC Form 25-NSE filed by BlackRock California Municipal Income Trust

    25-NSE - BLACKROCK CALIFORNIA MUNICIPAL INCOME TRUST (0001137391) (Subject)

    2/9/26 10:45:21 AM ET
    $BFZ
    Finance Companies
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

    SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

    2/5/26 1:16:32 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form N-CSRS filed by Nuveen Massachusetts Quality Municipal Income Fund

    N-CSRS - NUVEEN MASSACHUSETTS QUALITY MUNICIPAL INCOME FUND (0000897419) (Filer)

    2/5/26 11:15:41 AM ET
    $NMT
    Finance/Investors Services
    Finance

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2024 - FDA Roundup: March 26, 2024

    For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

    3/26/24 3:38:14 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

    3/22/24 1:48:21 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

    11/15/22 5:01:07 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summerton Rhys was granted 33,898 shares, increasing direct ownership by 234% to 48,391 units (SEC Form 4)

    4 - Childrens Place, Inc. (0001041859) (Issuer)

    2/5/26 4:32:23 PM ET
    $PLCE
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Edwards Douglas R was granted 33,898 shares, increasing direct ownership by 141% to 57,922 units (SEC Form 4)

    4 - Childrens Place, Inc. (0001041859) (Issuer)

    2/5/26 4:31:19 PM ET
    $PLCE
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Arshad Hussan was granted 33,898 shares, increasing direct ownership by 148% to 56,865 units (SEC Form 4)

    4 - Childrens Place, Inc. (0001041859) (Issuer)

    2/5/26 4:30:27 PM ET
    $PLCE
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Appoints William H. White as Chief Financial Officer

    Seasoned finance executive brings growth-focused mindset to advancing Quantum's long-term strategy Quantum Corporation (NASDAQ:QMCO) today announced the appointment of William H. White as its Chief Financial Officer. White will lead Quantum's global finance organization, including financial strategy and operations, capital structure initiatives, and investor relations, supporting the company's next phase of growth and operational execution. White brings more than two decades of experience transforming technology companies through disciplined financial leadership and strategic capital allocation. He is recognized for improving operational rigor and modernizing reporting and forecasting p

    2/2/26 8:00:00 AM ET
    $QMCO
    Electronic Components
    Technology

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hooker Furnishings to Appoint New Independent Director with Industry Expertise

    Enters Cooperation Agreement with GVIC Announces Retirement of Board Chair Chris Beeler at 2026 Annual Meeting Following 33 Years of Service to Hooker MARTINSVILLE, Va., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) ("Hooker" or the "Company"), a global leader in home furnishings, today announced it has entered into a cooperation agreement (the "Agreement") with Global Value Investment Corporation ("GVIC") under which GVIC and the Company will work together in good faith to identify a mutually agreeable independent director with industry expertise within 45 days of signing the Agreement. Once the agreed upon director is identified and properly vetted,

    1/2/26 4:01:00 PM ET
    $HOFT
    Home Furnishings
    Consumer Discretionary

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Financials

    Live finance-specific insights

    View All

    Quantum to Announce Fiscal Third Quarter 2026 Financial Results on February 17, 2026

    Quantum Corporation (NASDAQ:QMCO) ("Quantum" or the "Company"), today announced it will release financial results for its fiscal third quarter 2026 on Tuesday, February 17, 2026, after the markets close. Hugues Meyrath, Chief Executive Officer, and William White, Chief Financial Officer, will host a conference call on Tuesday, February 17, 2026 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the Company's financial results and business outlook. Analysts and investors are invited to join the conference call using the following information: Date: Tuesday, February 17, 2026 Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Call Number: 1-866-424-3436 International Call Number: +

    2/9/26 4:05:00 PM ET
    $QMCO
    Electronic Components
    Technology

    BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) Announces Distribution

    BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE:DMB) today announced a distribution of $0.0420 per share of common stock, payable on March 2, 2026 to shareholders of record at the close of business on February 18, 2026. The ex-dividend date is February 18, 2026. The previous distribution announced in January was $0.0420 per share of common stock. The Fund intends to make regular monthly distributions to its common shareholders at a level rate based on its projected performance. At times, to maintain a stable level of distributions, the Fund may pay out less than all of its net investment income or, in addition to paying out current net investment income, the Fund may pay out acc

    2/3/26 4:08:00 PM ET
    $BK
    $DMB
    Major Banks
    Finance
    Trusts Except Educational Religious and Charitable

    Invesco Closed-End Funds Declare Dividends

    ATLANTA, Feb. 2, 2026 /PRNewswire/ -- The Board of Trustees of each of the Invesco closed-end funds listed below declared dividends. EX-DATE RECORD DATE REINVEST DATE PAYABLE DATE 2/17/2026 2/17/2026 2/27/2026 2/27/2026   Name of Closed-EndManagement Investment Company   Ticker MonthlyDividend Per Share Change FromPriorDistribution % ChangeFrom PriorDistribution Invesco Advantage Municipal Income Trust II VKI $0.05591 - - Invesco Bond Fund VBF $0.06651 -0.0035 -5 % Invesco California Value Municipal Income Trust   VCV $0.06461 - - Invesco High Income Trust II VLT $0.09401

    2/2/26 12:00:00 PM ET
    $IIM
    $IQI
    $IVZ
    Investment Managers
    Finance
    Finance Companies
    Trusts Except Educational Religious and Charitable

    $ACLX
    $ADGI
    $AKAN
    $ALNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BNY Mellon Municipal Bond Infrastructure Fund Inc.

    SC 13D/A - BNY Mellon Municipal Bond Infrastructure Fund, Inc. (0001565381) (Subject)

    12/13/24 4:29:03 PM ET
    $DMB
    Trusts Except Educational Religious and Charitable
    Finance

    Amendment: SEC Form SC 13D/A filed by Nuveen New York Quality Municipal Income Fund

    SC 13D/A - NUVEEN NEW YORK QUALITY MUNICIPAL INCOME FUND (0001074769) (Subject)

    12/13/24 4:15:18 PM ET
    $NAN
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by Invesco Trust for Investment Grade New York Municipals

    SC 13D/A - Invesco Trust for Investment Grade New York Municipals (0000883265) (Subject)

    12/13/24 4:09:26 PM ET
    $VTN
    Finance Companies
    Finance